Gossamer Bio Inc. (GOSS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Gossamer Bio Inc. (GOSS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.86

-0.06 (-6.82%)

At close: Jan 14, 2025, 3:59 PM

0.92

6.80%

Pre-market Jan 15, 2025, 06:03 AM EST

undefined% (undefined)

Bid	0.86
Market Cap	194.56M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.25
PE Ratio (ttm)	-3.43
Forward PE	n/a
Analyst	Buy

Ask	0.87
Volume	744,660
Avg. Volume (20D)	1,372,075
Open	0.93
Previous Close	0.92
Day's Range	0.82 - 0.94
52-Week Range	0.50 - 1.60
Beta	undefined

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hy...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 8, 2019

Employees 135

Stock Exchange NASDAQ

Ticker Symbol GOSS

Website https://www.gossamerbio.com

Analyst Forecast

According to 5 analyst ratings, the average rating for GOSS stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 948.22% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Gossamer Bio Inc. is scheduled to release its earnings on Mar 4, 2025, before market opens.
Analysts project revenue of $7.02M, reflecting a n/a YoY growth and earnings per share of -0.17, making a -19.05% decrease YoY.

Why Price Moved

6 months ago · Source

+22.26%

Gossamer Bio shares are trading higher after Oppen... Unlock content with Pro Subscription

7 months ago · Source

+0.02%

Gossamer Bio shares are trading higher after competitor Aerovate Therapeutics reported topline results from the Phase 2b portion of IMPAHCT trial of AV-101 for pulmonary arterial hypertension.

News

1 week ago · businesswire.com

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary...

2 weeks ago · zacks.com

Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · zacks.com

After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)

Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revis...

2 months ago · zacks.com

After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)

The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys...

2 months ago · zacks.com

Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago.